阿里拉姆制藥股票討論區

$Annovis Bio(ANVS.US)$ 22% Ph2/3 data reporting update
$Taysha Gene Therapies(TSHA.US)$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US)$ 14% Clinical programs update
$Jaguar Health(JAGX.US)$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US)$ 4% Ph1/2 positive data
$迪卡斯(DCTH.US)$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US)$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US)$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US)$ 0...

🎯 Ph 3 readouts in Q1 2024...
$輝瑞(PFE.US)$  Phase 3
$Palatin Technologies(PTN.US)$  Phase 3
$Annovis Bio(ANVS.US)$  Phase 3
$BioCardia(BCDA.US)$  Phase 3
$Atea Pharmaceuticals(AVIR.US)$  Phase 3
$Ironwood醫藥(IRWD.US)$  Phase 3
$阿里拉姆制藥(ALNY.US)$  Phase 3
$Axsome Therapeutics(AXSM.US)$  Phase 3
$$Novocure(NVCR.US)$  Phase 3
$羅氏(ADR)(RHHBY.US)$  Phase 3
$FibroGen(FGEN.US)$  Phase 3
$阿卡迪亞(ACAD.US)$  Phase 3
$Sellas Life Sciences(SLS.US)$...

$輝瑞(PFE.US)$  Phase 3
$Regenxbio(RGNX.US)$  Phase 3
$Annovis Bio(ANVS.US)$  Phase 3
$Atea Pharmaceuticals(AVIR.US)$  Phase 3
$Ironwood醫藥(IRWD.US)$  Phase 3
$阿里拉姆制藥(ALNY.US)$  Phase 3
$福泰製藥(VRTX.US)$  Phase 3
$KalVista Pharmaceuticals(KALV.US)$  Phase 3
$Axsome Therapeutics(AXSM.US)$  Phase 3
$Novocure(NVCR.US)$  Phase 3
$羅氏(ADR)(RHHBY.US)$  Phase 3
$FibroGen(FGEN.US)$  Phase 3
$Applied Therapeutics(APLT.US)$  Phase 3
$阿卡迪亞(ACAD.US)$  Phase 3...

$輝瑞(PFE.US)$  Phase 2
$Leap Therapeutics(LPTX.US)$  Phase 2
$Vera Therapeutics(VERA.US)$  Phase 2b
$4D Molecular Therapeutics(FDMT.US)$  Phase 2
$Adverum Biotechnologies(ADVM.US)$  Phase 2
$Denali Therapeutics(DNLI.US)$  Phase 2
$Akero Therapeutics(AKRO.US)$  Phase 2b
$Spruce Biosciences(SPRB.US)$  Phase 2
$Xencor(XNCR.US)$  Phase 2
$阿里拉姆制藥(ALNY.US)$  Phase 2
$Harmony Biosciences(HRMY.US)$  Phase 2
$Annexon(ANNX.US)$  Phase 2a
$Roivant Sciences(ROIV.US)$...

$Cellectar BioSciences(CLRB.US)$ Phase 2
$Regenxbio(RGNX.US)$ Phase 2
$Leap Therapeutics(LPTX.US)$ Phase 2
$4D Molecular Therapeutics(FDMT.US)$ Phase 2
$Adverum Biotechnologies(ADVM.US)$ Phase 2
$Denali Therapeutics(DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US)$ Phase 2
$Xencor(XNCR.US)$ Phase 2
$Harmony Biosciences(HRMY.US)$ Phase 2
$阿里拉姆制藥(ALNY.US)$ Phase 2
$Disc Medicine(IRON.US)$ Phase 2
$Atea Pharmaceuticals(AVIR.US)$ Phase 2
$Allakos(ALLK.US)$ Phase 2...

Gapping up
In reaction to earnings/guidance:
• $Aehr Test Systems(AEHR.US)$ +11.1% (also releases two new enhancements for its FOX-P family of wafer level test and burn-in systems)
• $Tilray Brands(TLRY.US)$ +5.1%
Other news:
• $Payoneer Global(PAYO.US)$ +8.1% (to join SaP SmallCap 600)
• $Atlas(ATCO.US)$ +6.8% (continues negotiations with Poseidon Acquisition; parties have made meaningful progress on potential transactio...

Upgrades
• $汽車地帶(AZO.US)$ : Goldman Sachs Upgrades to Buy from Neutral - PT $2,296 (from $1,969)
• $Chewy(CHWY.US)$ : Needham Upgrades to Buy from Hold - PT $55
• $National Vision(EYE.US)$ : Goldman Sachs Upgrades to Buy from Neutral - PT $32 (from $31)
• $費森尤斯醫療(FMS.US)$ : Jefferies Upgrades to Buy from Underperform - PT $33.70 (from $30.30)
• $Gitlab(GTLB.US)$ : Goldman Sachs Upgrades to Buy from Neutral - ...